Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064963 | 1.00 | DRD1 (0.35) | DRD1HHATKMT2ATRPC3TRPC6 | |
| SCHEMBL20064968 | 0.89 | DRD1 (0.35) | DRD1HHATKMT2ATRPC3TRPC6 | |
| SCHEMBL20064967 | 0.89 | DRD1 (0.35) | DRD1HHATKMT2ATRPC3TRPC6 | |
| SCHEMBL20064962 | 0.88 | DRD1 (0.35) | DRD1HHATKMT2ATRPC3TRPC6 | |
| SCHEMBL20064964 | 0.88 | DRD1 (0.35) | DRD1HHATKMT2ATRPC3TRPC6 | |
| SCHEMBL22654449 | 0.87 | MGLL (0.31) | — | |
| SCHEMBL22688408 | 0.87 | MGLL (0.31) | — | |
| SCHEMBL22491949 | 0.86 | TRPC3 (0.41) | DRD1TRPC3TRPC6 | |
| SCHEMBL29429523 | 0.86 | TRPC3 (0.41) | DRD1TRPC3TRPC6 | |
| SCHEMBL18198502 | 0.86 | TRPC3 (0.41) | DRD1TRPC3TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2019149734-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | ACE, ACE2, PTBP1 | DRD1 4225/4885HHAT 2438/4885KMT2A 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.